ANDROGENREZEPTOR-ANTISENSE-OLIGONUKLEOTIDE

Patent europeic · EP3497114 · En vigur

Inscripziun en il register

Numer da publicaziun
EP3497114
Numer da la dumonda
EP17838864
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
24-05-2017
Publitgà
19-06-2019
Concedì
16-10-2024
La protecziun finescha il pli tard
23-05-2037
Proxima taxa annuala scadenta
31-05-2026
Classas IPC
C12N 15/113 (2010.01)
C12N 15/11 (2006.01)
Prioritad
US 201662372035 P 08.08.2016
Dumonda PCT
PCT/IB2017/000697 24.05.2017
Publicaziun PCT
WO2018/029517 15.02.2018
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 02-12-2025

    Midada

    Published in Swissreg on 02.12.2025

  2. 27-08-2025

    Midada

    Published in Swissreg on 27.08.2025

  3. 05-12-2024

    Represchentant inscrit

    Representative
    HGF GmbH, OBC Suisse AG, Aeschengraben 29, 4051 Basel

    Published in Swissreg on 05.12.2024

  4. 16-10-2024

    Concedì

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 16.10.2024

Partidas

Possessur

Olipass Corporation

20th Floor Ace Dongbaek Tower 16 Beon-gil 16-4 Dongbaek Jungang-ro Giheung-gu, Yongin-si, Gyeonggi-do 17105, KR

Represchentant

HGF GmbH

OBC Suisse AG Aeschengraben 29, 4051 Basel

Inventur

CHUNG, Shin

Yongin-si Gyeonggi-do 16990, KR

JUNG, Daram

Hwaseong-si Gyeonggi-do, KR

CHO, Bongjun

Yongin-si Gyeonggi-do 17077, KR

JANG, Kangwon

Yongin-si Gyeonggi-do 16998, KR

YOON, Heungsik

Seongnam-si Gyeonggi-do 13623, KR

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.